Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Purchased by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd increased its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 287.1% in the 4th quarter, HoldingsChannel reports. The fund owned 27,061 shares of the company’s stock after purchasing an additional 20,070 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Harmony Biosciences were worth $931,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its stake in shares of Harmony Biosciences by 92.6% in the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock valued at $31,000 after purchasing an additional 436 shares during the last quarter. Mendota Financial Group LLC lifted its position in Harmony Biosciences by 24,125.0% in the fourth quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock valued at $33,000 after buying an additional 965 shares during the last quarter. KBC Group NV boosted its stake in Harmony Biosciences by 79.9% during the fourth quarter. KBC Group NV now owns 1,844 shares of the company’s stock worth $63,000 after buying an additional 819 shares during the period. Quantbot Technologies LP purchased a new position in Harmony Biosciences during the third quarter worth about $74,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of Harmony Biosciences by 21.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,056 shares of the company’s stock valued at $80,000 after acquiring an additional 360 shares during the last quarter. Institutional investors and hedge funds own 86.23% of the company’s stock.

Insider Buying and Selling

In related news, CFO Sandip Kapadia sold 1,775 shares of the stock in a transaction on Monday, January 27th. The stock was sold at an average price of $38.05, for a total value of $67,538.75. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Jeffrey Dierks sold 10,507 shares of the firm’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $37.01, for a total value of $388,864.07. The disclosure for this sale can be found here. Insiders sold 72,452 shares of company stock worth $2,831,679 over the last 90 days. 30.80% of the stock is owned by insiders.

Analyst Ratings Changes

HRMY has been the topic of several recent analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $50.00 price objective on shares of Harmony Biosciences in a research report on Tuesday. HC Wainwright lowered their price target on Harmony Biosciences from $75.00 to $70.00 and set a “buy” rating for the company in a research report on Thursday. Mizuho dropped their price objective on Harmony Biosciences from $52.00 to $42.00 and set an “outperform” rating for the company in a research note on Thursday, February 20th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on Harmony Biosciences in a research note on Tuesday, February 11th. They set a “buy” rating and a $55.00 target price on the stock. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $53.11.

Harmony Biosciences Stock Down 2.2 %

Shares of NASDAQ HRMY opened at $32.75 on Friday. Harmony Biosciences Holdings, Inc. has a 12-month low of $28.14 and a 12-month high of $41.61. The stock has a market cap of $1.87 billion, a P/E ratio of 15.52, a PEG ratio of 0.47 and a beta of 0.80. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. The business’s fifty day simple moving average is $36.66 and its 200-day simple moving average is $35.81.

Harmony Biosciences (NASDAQ:HRMY) last announced its quarterly earnings data on Tuesday, February 25th. The company reported $0.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.11. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The business had revenue of $201.30 million during the quarter, compared to analysts’ expectations of $201.25 million. During the same quarter last year, the business posted $0.45 EPS. The business’s quarterly revenue was up 19.5% compared to the same quarter last year. As a group, equities analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.